Navigation Links
Cardium Reports On Third Quarter 2013 Financial Results And Recent Business Developments
Date:11/19/2013

um will be successful in advancing, capitalizing and partnering or monetizing its other businesses and technology platforms; that the Company can raise capital through the private or public sale of equity interests on a company-by-company basis or otherwise; that planned product development efforts and clinical studies can be performed in an efficient and effective manner; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the Company or its partners will be successful in developing and marketing survivable risk life insurance programs or that any intellectual property developed in the area will be effective for excluding potential competitors; that the Company will satisfy the requirements of its exchange listing compliance plan and will otherwise continue to satisfy the listing requirements of its exchange or that its shares can continue to be listed on a national exchange; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that our or our licensor's intellectual property can be successfully developed and enforced and that we will not be accused of infringing on intellectual property developed by third parties; that the products and product candidates referred to in this report or
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Unusual Trading Activity In Cardium Common Stock
2. Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells
3. Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties
4. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
5. Cardium Completes Preferred Stock Financing
6. Cardium Announces Reverse Stock Split
7. Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013
8. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
9. Cardium Announces Generx Publication In Molecular Therapy
10. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
11. Cardium Presents Year-End 2012 Financial Results And Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The Healthcare Analytics Summit 2014 ... Salt Lake City , Sept. 24-25 ... respected healthcare organizations in the U.S. and beyond.  HAS ... industry conference devoted to providing immersive learning experiences on ... of both accountable care initiatives and population health ...
(Date:7/29/2014)... IRVING, Texas , July 29, 2014 /PRNewswire/ ... three new web-based applications with breakthrough interactive features ... and workflows for members of Children,s Hospital Association.  ... under the Novation Optimize Solutions umbrella – Value ... of how Novation helps organizations address the most ...
(Date:7/29/2014)... DIEGO , July 29, 2014   ... Nancy Thornberry to its board of ... franchise head, Diabetes and Endocrinology for Merck & ... strategy and overall pipeline management in diabetes, osteoporosis, ... initiated and co-led the program that resulted in ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Research, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- ... that,(1) demonstrate that Azixa(TM) (MPC-6827) is effective in ... (2) reveal a,mechanism by which MPC-6827 exerts its ... by cellular proteins known to be involved,in cancer ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... improvement measures in eight of the 10 hospitals in ... have found a way to reduce kidney injury in ... 7-15 percent of these patients who undergo a coronary ... which can result in death or rapid decline in ... a study published in the July issue of ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... Avenidas is always looking for ways to ... non-profit agency is doing just that with the Third Annual ... event gives seniors the opportunity to learn about how they ... a variety of fun activities, including a Tai Chi demonstration, ... In addition, there will be food tastings, courtesy of Lyfe ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... - Researchers from the Boston University School of Medicine ... a $3.5 million grant from the National Institute on ... treat, and retain" paradigm in Eastern Europe among HIV-infected ... narcology (addiction) care. The project will be known as ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... Mozes HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... people to develop cancer, new British research says. Among ... leukemia or melanoma appears to go up about 16 percent ... "Taller women in our study had increased risk of a ...
... , THURSDAY, July 21 (HealthDay News) -- A new U.S. ... to use the Internet for medical information, and whites are ... the findings released Thursday by the U.S. National Center for ... as likely as Hispanics to search for health information online. ...
... National Nanotechnology Initiative,s (NNI) released four reports that ... focusing on various issues in the nanotechnology environmental, ... series was a part of an ongoing strategy ... from industry, academia, and the Federal Government to ...
... the first time created a way of measuring how much force ... advance is expected to have significant implications for legal forensics. ... the force applied during a stabbing and come up with the ... work has been published in the International Journal of Legal ...
Cached Medicine News:Health News:BUSM/BMC researchers awarded $3.5 million grant from the NIDA 2Health News:Minority participants crucial to effective aging studies 2Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Women, Whites Most Likely to Seek Health Info Online: Survey 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 3
... offers the ease and comfort you've come to ... users in clinical trials agreed that the BD ... depth settings allow you to choose the best ... of lancets, the device also helps eliminate the ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
... The StaRRsed Compact is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: